RadNet, Inc. (NASDAQ:RDNT) Receives $88.14 Consensus PT from Analysts

Posted by George Bondi on May 13th, 2026

RadNet, Inc. (NASDAQ:RDNT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $88.1429.

RDNT has been the subject of a number of analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $91.00 price target on shares of RadNet in a research note on Tuesday, March 3rd. Barclays dropped their price target on RadNet from $86.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, April 21st.

Get Our Latest Research Report on RadNet

Insider Buying and Selling

In related news, insider Alma Gregory Sorensen sold 15,000 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $62.15, for a total value of $932,250.00. Following the completion of the transaction, the insider owned 1,208,923 shares of the company’s stock, valued at $75,134,564.45. The trade was a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. acquired a new position in RadNet in the fourth quarter valued at about $25,000. Allworth Financial LP raised its stake in RadNet by 346.6% in the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 305 shares in the last quarter. Danske Bank A S acquired a new position in RadNet in the third quarter valued at about $30,000. Farther Finance Advisors LLC grew its position in RadNet by 1,086.5% in the third quarter. Farther Finance Advisors LLC now owns 439 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 402 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in RadNet by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 446 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 171 shares during the last quarter. Institutional investors and hedge funds own 77.90% of the company’s stock.

RadNet News Summary

Here are the key news stories impacting RadNet this week:

Positive Sentiment: RadNet reported record first-quarter revenue of $575.63 million, up 22.1% year over year and above analyst expectations, showing continued demand for its imaging services. Press Release
Positive Sentiment: The company raised its 2026 imaging center guidance for revenue, adjusted EBITDA and free cash flow, signaling management is more confident about the year ahead. Guidance Update
Neutral Sentiment: Quarterly EPS came in at -$0.28, missing the consensus estimate of $0.19, so profitability remains a concern despite the revenue beat. Earnings Transcript
Neutral Sentiment: Investor focus also remains on the earnings call details and management commentary, which may help explain how RadNet plans to convert strong revenue growth into better margins over time. Earnings Call Transcript
Negative Sentiment: The earnings miss and continued negative net margin highlight that RadNet is still not consistently translating sales growth into bottom-line earnings, which could limit upside. Transcript

RadNet Stock Up 0.2%

RDNT opened at $56.00 on Wednesday. RadNet has a fifty-two week low of $50.76 and a fifty-two week high of $85.84. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.76 and a current ratio of 1.17. The company has a market capitalization of $4.38 billion, a P/E ratio of -311.09 and a beta of 1.43. The stock has a fifty day moving average of $59.43 and a 200-day moving average of $69.32.

RadNet (NASDAQ:RDNT – Get Free Report) last posted its earnings results on Monday, May 11th. The medical research company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The firm had revenue of $575.63 million for the quarter, compared to analyst estimates of $557.93 million. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.50) EPS. On average, equities analysts expect that RadNet will post 0.62 EPS for the current year.

RadNet Company Profile

(Get Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.